|
|
Volumn 339, Issue , 2009, Pages
|
|
NICE rules that drug used in advanced liver cancer is not cost effective for the NHS.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BENZENESULFONIC ACID DERIVATIVE;
PYRIDINE DERIVATIVE;
SORAFENIB;
COST BENEFIT ANALYSIS;
ECONOMICS;
HUMAN;
LIVER TUMOR;
NOTE;
QUALITY ADJUSTED LIFE YEAR;
UNITED KINGDOM;
ANTINEOPLASTIC AGENTS;
BENZENESULFONATES;
COST-BENEFIT ANALYSIS;
GREAT BRITAIN;
HUMANS;
LIVER NEOPLASMS;
PYRIDINES;
QUALITY-ADJUSTED LIFE YEARS;
|
|
EID: 79958170471
PISSN: None
EISSN: 14685833
Source Type: Journal
DOI: 10.1136/bmj.b4956 Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|
